Kangmei Pharmaceutical Co., Ltd.
Chinese traditional medicine manufacturer that fabricated 30 billion yuan ($4.4B) in cash balances, later blamed by management on a 'clerical error'.
- Entity Name: Kangmei Pharmaceutical Co., Ltd.
- Country of Domicile: CN
- Listing & Ticker: SSE (600518).
- CIK / LEI Identifier: Unregistered.
- Industry Classification: Pharmaceutical Preparations (SIC 2834).
- Cumulative Overstatement: $4.4B across 1 enforcement episode(s).
- Assessed Penalties: $350.0M.
PRIMARY ENFORCEMENT CASES INVOLVING KANGMEI PHARMACEUTICAL CO., LTD.
1 CASE DOSSIERS| Case Title | Status | Primary Scheme | Overstatement | Total Penalties | Action Date |
|---|---|---|---|---|---|
| Kangmei Pharmaceutical: 30 Billion Yuan ($4.4B) Fabricated Cash Balances | Adjudicated | fictitious cash and assets | $4.4B | $350.0M | September 20, 2021 |
FORENSIC PROFILE: KANGMEI PHARMACEUTICAL: 30 BILLION YUAN ($4.4B) FABRICATED CASH BALANCES
FULL CASE DOSSIER →Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'.
The company manipulated its accounting records by executing schemes under fictitious-cash-and-assets. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.
Fraud Window: January 1, 2019 to December 31, 2021 • Primary Regulator: China Securities Regulatory Commission (CSRC) • Auditor: Ernst & Young LLP
Documented Accounting Irregularities & Regulatory Findings
- FICTITIOUS CASH AND ASSETS: Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'.
Primary Public Dockets & Actions
- [ENF-2019-kangmei-pharma] Enforcement Action: Kangmei Pharmaceutical: 30 Billion Yuan ($4.4B) Fabricated Cash Balances (September 20, 2021): Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'. Official Record ↗